Trial Profile
A Phase 1B Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan-High Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Hyaluronidase (Primary) ; Pembrolizumab
- Indications Adenocarcinoma; Gastric cancer; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Halozyme Therapeutics
- 21 May 2019 Status changed from active, no longer recruiting to completed.
- 18 Dec 2018 Planned End Date changed from 1 Dec 2019 to 30 Jun 2019.
- 18 Dec 2018 Planned primary completion date changed from 1 Jun 2019 to 19 May 2019.